KT2
General Information
DRACP ID DRACP00869
Peptide Name KT2
Sequence NGVQPKYKWWKWWKKWW
Sequence Length 17
UniProt ID Not available
PubChem CID Not available
Origin AMP
Type Synthetic peptide
Classification
Active ACP
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
HCT 116 | Colon carcinoma | Carcinoma | IC50=50 µM | MTT assay | 24h | 1 |
A431 | Skin squamous cell carcinoma | Carcinoma | 34% Cytotoxicity=10 µM | MTT assay | 24h | 1 |
MDA-MB-231 | Breast adenocarcinoma | Carcinoma | Not active up to 10 µM | MTT assay | 24h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism KT2 interacts with the plasma membrane and is then internalized into cells. Moreover, the KT2 peptide increases membrane permeability and induces cytotoxicity against cancer cells through DNA condensation, the increase of apoptotic factor protein levels, and autophagy suppression.
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Cys2<--->Gly11
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification None
Chiral L
Physicochemical Information
Formula C126H164N30O21
Absent amino acids ACDEFHILMRST
Common amino acids W
Mass 272044
Pl 11.02
Basic residues 5
Acidic residues 0
Hydrophobic residues 7
Net charge 5
Boman Index -2111
Hydrophobicity -182.35
Aliphatic Index 17.06
Half Life
Mammalian: 2.8 hour
Yeast: 3 min
E.coli: 2 min
Extinction Coefficient cystines 34490
Absorbance 280nm 2155.63
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 31073999
Title The cationic cell-penetrating KT2 peptide promotes cell membrane defects and apoptosis with autophagy inhibition in human HCT 116 colon cancer cells
Year 2019
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available